Compare Aurora Cannabis Inc (ACB) vs Nasdaq100 ETF (QQQ) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

QQQ trades at $709.43, down 0.45% on the day, with a bullish technical signal from moving averages but neutral oscillators. Analyst consensus is split evenly between buy and sell recommendations. Recent news highlights SpaceX's inclusion in the Nasdaq-100, potentially adding modest exposure to the ETF. The ETF's performance remains tied to large-cap tech stocks, with historical volatility higher than broader market indices.

Outlook is mixed: technical strength supports near-term upside, but valuation concerns and divided analyst sentiment suggest caution. Key risks include tech sector concentration and macroeconomic pressures. Investment opportunity lies in continued tech leadership, though investors should weigh high volatility against growth potential.